Loss of STAT5 causes Liver fbrosis and cancer development through increased TGF-β and STAT3 activation

Journal of Experimental Medicine

Volumn 206, Issue 4, 2009, Pages 819-831

  Hosui, Atsushi ^a,b   Kimura, Akiko ^a   Yamaji, Daisuke ^a   Zhu, Bing Mei ^a   Na, Risu ^a   Hennighausen, Lothar ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; STAT3 PROTEIN; STAT5 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; CARBON TETRACHLORIDE; FIBRINOGEN GAMMA'; FIBRINOGEN VARIANT; HAPTOGLOBIN; STAT3 PROTEIN, MOUSE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; EMBRYO; EXPERIMENTAL MOUSE; FIBROBLAST; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VIVO STUDY; LIVER CELL; LIVER FIBROSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ANIMAL; CYTOLOGY; DISEASE COURSE; GENE DELETION; GENETICS; LIVER; LIVER CIRRHOSIS; LIVER TUMOR; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CARBON TETRACHLORIDE; DISEASE PROGRESSION; FIBRINOGENS, ABNORMAL; GENE DELETION; HAPTOGLOBINS; HEPATOCYTES; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MICE; MICE, KNOCKOUT; STAT3 TRANSCRIPTION FACTOR; STAT5 TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA;

EID: 65549094595     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20080003     Document Type: Article

References (54)

1. Yoshikawa, H., K. Matsubara, G.S. Qian, P. Jackson, J.D. Groopman, J.E. Manning, C.C. Harris, and J.G. Herman. 2001. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat. Genet. 28:29-35.
2. Satoh, S., Y. Daigo, Y. Furukawa, T. Kato, N. Miwa, T. Nishiwaki, T. Kawasoe, H. Ishiguro, M. Fujita, T. Tokino, et al. 2000. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet. 24:245-250.
3. Raghow, R., A.E. Postlethwaite, J. Keski-Oja, H.L. Moses, and A.H. Kang. 1987. Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J. Clin. Invest. 79:1285-1288.
4. Czaja, M.J., F.R. Weiner, K.C. Flanders, M.A. Giambrone, R. Wind, L. Biempica, and M.A. Zern. 1989. In vitro and in vivo association of transforming growth factor with hepatic fibrosis. J. Cell Biol. 108:2477-2482.
5. Derynck, R., J.A. Jarrett, E.Y. Chen, D.H. Eaton, J.R. Bell, R.K. Assoian, A.B. Roberts, M.B. Sporn, and D.V. Goeddel. 1985. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature. 316:701-705.
6. de Martin, R., B. Haendler, R. Hofer-Warbinek, H. Gaugitsch, M. Wrann, H. Schlusener, J.M. Seifert, S. Bodmer, A. Fontana, and E. Hofer. 1987. Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family. EMBO J. 6:3673-3677.
7. Hyytiainen, M., C. Penttinen, and J. Keski-Oja. 2004. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit. Rev. Clin. Lab. Sci. 41:233-264.
8. Bromberg, J.F., M.H. Wrzeszczynska, G. Devgan, Y. Zhao, R.G. Pestell, C. Albanese, and J.E. Darnell Jr. 1999. Stat3 as an oncogene. Cell. 98:295-303.
9. Frank, D.A. 1999. STAT signaling in the pathogenesis and treatment of cancer. Mol. Med. 5:432-456.
10. Grandis, J.R., S.D. Drenning, A. Chakraborty, M.Y. Zhou, Q. Zeng, A.S. Pitt, and D.J. Tweardy. 1998. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor- mediated cell growth In vitro. J. Clin. Invest. 102:1385-1392.
11. Catlett-Falcone, R., T.H. Landowski, M.M. Oshiro, J. Turkson, A. Levitzki, R. Savino, G. Ciliberto, L. Moscinski, J.L. Fernandez-Luna, G. Nunez, et al. 1999. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 10:105-115.
12. Migone, T.S., J.X. Lin, A. Cereseto, J.C. Mulloy, J.J. Shea, G. Franchini, and W.J. Leonard. 1995. Constitutively activated Jak-STAT pathway in T cells transformed with HTLV-I. Science. 269:79-81.
13. Shuai, K., J. Halpern, J. ten Hoeve, X. Rao, and C.L. Sawyers. 1996. Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene. 13:247-254.
14. Moriggl, R., D.J. Topham, S. Teglund, V. Sexl, C. McKay, D. Wang, A. Hoffmeyer, J. van Deursen, M.Y. Sangster, K.D. Bunting, et al. 1999. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity. 10:249-259.
15. Socolovsky, M., A.E. Fallon, S. Wang, C. Brugnara, and H.F. Lodish. 1999. Fetal anemia and apoptosis of red cell progenitors in Stat5a/5b/mice: a direct role for Stat5 in Bcl-X(L) induction. Cell. 98:181-191.
16. Zhang, Q., H.Y. Wang, X. Liu, and M.A. Wasik. 2007. STAT5A is epigenetically silenced by the tyrosine kinase NPM1-ALK and acts as a tumor suppressor by reciprocally inhibiting NPM1-ALK expression. Nat. Med. 13:1341-1348.
17. Xi, S., Q. Zhang, W.E. Gooding, T.E. Smithgall, and J.R. Grandis. 2003. Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res. 63:6763-6771.
18. Kannangai, R., F. Sahin, and M.S. Torbenson. 2006. EGFR is phosphorylated at Ty845 in hepatocellular carcinoma. Mod. Pathol. 19:1456-1461.
19. Lee, T.K., K. Man, R.T. Poon, C.M. Lo, A.P. Yuen, I.O. Ng, K.T. Ng, W. Leonard, and S.T. Fan. 2006. Signal transducers and activators of transcription 5b activation enhances hepatocellular carcinoma aggressiveness through induction of epithelial-mesenchymal transition. Cancer Res. 66:9948-9956.
20. Miyazono, K., A. Olofsson, P. Colosetti, and C.H. Heldin. 1991. A role of the latent TGF-beta 1-binding protein in the assembly and secretion of TGF-beta 1. EMBO J. 10:1091-1101.
21. Drews, F., S. Knobel, M. Moser, K.G. Muhlack, S. Mohren, C. Stoll, A. Bosio, A.M. Gressner, and R. Weiskirchen. 2008. Disruption of the latent transforming growth factor-beta binding protein-1 gene causes alteration in facial structure and inf luences TGF-beta bioavailability. Biochim. Biophys. Acta. 1783:34-48.
22. Moller, S., U. Becker, M. Gronbaek, A. Juul, K. Winkler, and N.E. Skakkebaek. 1994. Short-term effect of recombinant human growth hormone in patients with alcoholic cirrhosis. J. Hepatol. 21:710-717.
23. Shen, X.Y., R.I. Holt, J.P. Miell, S. Justice, B. Portmann, M.C. Postel-Vinay, and R.J. Ross. 1998. Cirrhotic liver expresses low levels of the fulllength and truncated growth hormone receptors. J. Clin. Endocrinol. Metab. 83:2532-2538.
24. Cui, Y., A. Hosui, R. Sun, K. Shen, O. Gavrilova, W. Chen, M.C. Cam, B. Gao, G.W. Robinson, and L. Hennighausen. 2007. Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration. Hepatology. 46:504-513.
25. Hosui, A., and L. Hennighausen. 2008. Genomic dissection of the cytokine controlled STAT5 signaling network in liver. Physiol. Genomics. 34:135-143.
26. Moses, H.L., R.J. Coffey Jr., E.B. Leof, R.M. Lyons, and J. Keski-Oja. 1987. Transforming growth factor beta regulation of cell proliferation. J. Cell. Physiol. Suppl. 133:1-7.
27. Wood, T.J., D. Sliva, P.E. Lobie, T.J. Pircher, F. Gouilleux, H. Wakao, J.A. Gustafsson, B. Groner, G. Norstedt, and L.A. Haldosen. 1995. Mediation of growth hormone-dependent transcriptional activation by mammary gland factor/Stat 5. J. Biol. Chem. 270:9448-9453.
28. Beuvink, I., D. Hess, H. Flotow, J. Hofsteenge, B. Groner, and N.E. Hynes. 2000. Stat5a serine phosphorylation. Serine 779 is constitutively phosphorylated in the mammary gland, and serine 725 phosphorylation inf luences prolactin-stimulated in vitro DNA binding activity. J. Biol. Chem. 275:10247-10255.
29. Gewinner, C., G. Hart, N. Zachara, R. Cole, C. Beisenherz-Huss, and B. Groner. 2004. The coactivator of transcription CREB-binding protein interacts preferentially with the glycosylated form of Stat5. J. Biol. Chem. 279:3563-3572.
30. Darnell, J.E. Jr. 1997. STATs and gene regulation. Science. 277:1630-1635.
31. Teglund, S., C. McKay, E. Schuetz, J.M. van Deursen, D. Stravopodis, D. Wang, M. Brown, S. Bodner, G. Grosveld, and J.N. Ihle. 1998. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 93:841-850.
32. Donaghy, A., R. Ross, A. Gimson, S.C. Hughes, J. Holly, and R. Williams. 1995. Growth hormone, insulinlike growth factor-1, and insulinlike growth factor binding proteins 1 and 3 in chronic liver disease. Hepatology. 21:680-688.
33. Cui, Y., G. Riedlinger, K. Miyoshi, W. Tang, C. Li, C.X. Deng, G.W. Robinson, and L. Hennighausen. 2004. Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol. Cell. Biol. 24:8037-8047.
34. Hoelbl, A., B. Kovacic, M.A. Kerenyi, O. Simma, W. Warsch, Y. Cui, H. Beug, L. Hennighausen, R. Moriggl, and V. Sexl. 2006. Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. Blood. 107:4898-4906.
35. Yao, Z., Y. Cui, W.T. Watford, J.H. Bream, K. Yamaoka, B.D. Hissong, D. Li, S.K. Durum, Q. Jiang, A. Bhandoola, et al. 2006. Stat5a/b are essential for normal lymphoid development and differentiation. Proc. Natl. Acad. Sci. USA. 103:1000-1005.
36. Li, G., Z. Wang, Y. Zhang, Z. Kang, E. Haviernikova, Y. Cui, L. Hennighausen, R. Moriggl, D. Wang, W. Tse, and K.D. Bunting. 2007. STAT5 requires the N-domain to maintain hematopoietic stem cell repopulating function and appropriate lymphoid-myeloid lineage output. Exp. Hematol. 35:1684-1694.
37. Moriggl, R., V. Sexl, L. Kenner, C. Duntsch, K. Stangl, S. Gingras, A. Hoffmeyer, A. Bauer, R. Piekorz, D. Wang, et al. 2005. Stat5 tetramer formation is associated with leukemogenesis. Cancer Cell. 7:87-99.
38. Thomas, D.A., and J. Massague. 2005. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 8:369-380.
39. Wang, T., G. Niu, M. Kortylewski, L. Burdelya, K. Shain, S. Zhang, R. Bhattacharya, D. Gabrilovich, R. Heller, D. Coppola, et al. 2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10:48-54.
40. Unitt, E., S.M. Rushbrook, A. Marshall, S. Davies, P. Gibbs, L.S. Morris, N. Coleman, and G.J. Alexander. 2005. Compromised lymphocytes infiltrate hepatocellular carcinoma: the role of T-regulatory cells. Hepatology. 41:722-730.
41. Seki, E., S. De Minicis, C.H. Osterreicher, J. Kluwe, Y. Osawa, D.A. Brenner, and R.F. Schwabe. 2007. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat. Med. 13:1324-1332.
42. Takehara, T., T. Tatsumi, T. Suzuki, E.B. Rucker III, L. Hennighausen, M. Jinushi, T. Miyagi, Y. Kanazawa, and N. Hayashi. 2004. Hepatocytespecific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology. 127:1189-1197.
43. Canbay, A., S. Friedman, and G.J. Gores. 2004. Apoptosis: the nexus of liver injury and fibrosis. Hepatology. 39:273-278.
44. Gao, C., G. Gressner, M. Zoremba, and A.M. Gressner. 1996. Transforming growth factor beta (TGF-beta) expression in isolated and cultured rat hepatocytes. J. Cell. Physiol. 167:394-405.
45. Jeong, W.I., S.H. Do, H.S. Yun, B.J. Song, S.J. Kim, W.J. Kwak, S.E. Yoo, H.Y. Park, and K.S. Jeong. 2004. Hypoxia potentiates transforming growth factor-beta expression of hepatocyte during the cirrhotic condition in rat liver. Liver Int. 24:658-668.
46. Kaimori, A., J. Potter, J.Y. Kaimori, C. Wang, E. Mezey, and A. Koteish. 2007. Transforming growth factor-beta1 induces an epithelialto- mesenchymal transition state in mouse hepatocytes in vitro. J. Biol. Chem. 282:22089-22101.
47. Iwano, M., D. Plieth, T.M. Danoff, C. Xue, H. Okada, and E.G. Neilson. 2002. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 110:341-350.
48. Stocklin, E., M. Wissler, F. Gouilleux, and B. Groner. 1996. Functional interactions between Stat5 and the glucocorticoid receptor. Nature. 383:726-728.
49. Park, S.H., C.A. Wiwi, and D.J. Waxman. 2006. Signalling cross-talk between hepatocyte nuclear factor 4alpha and growth-hormone-activated STAT5b. Biochem. J. 397:159-168.
50. Hennighausen, L., and G.W. Robinson. 2008. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev. 22:711-721.
51. Bernasconi, A., R. Marino, A. Ribas, J. Rossi, M. Ciaccio, M. Oleastro, A. Ornani, R. Paz, M.A. Rivarola, M. Zelazko, and A. Belgorosky. 2006. Characterization of immunodeficiency in a patient with growth hormone insensitivity secondary to a novel STAT5b gene mutation. Pediatrics. 118:e1584-e1592.
52. Kofoed, E.M., V. Hwa, B. Little, K.A. Woods, C.K. Buckway, J. Tsubaki, K.L. Pratt, L. Bezrodnik, H. Jasper, A. Tepper, et al. 2003. Growth hormone insensitivity associated with a STAT5b mutation. N. Engl. J. Med. 349:1139-1147.
53. Yakar, S., J.L. Liu, B. Stannard, A. Butler, D. Accili, B. Sauer, and D. LeRoith. 1999. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc. Natl. Acad. Sci. USA. 96:7324-7329.
54. Hosui, A., K. Ohkawa, H. Ishida, A. Sato, F. Nakanishi, K. Ueda, T. Takehara, A. Kasahara, Y. Sasaki, M. Hori, and N. Hayashi. 2003. Hepatitis C virus core protein differently regulates the JAK-STAT signaling pathway under interleukin-6 and interferon-gamma stimuli. J. Biol. Chem. 278:28562-28571.